Q1 Earnings Estimate for AKBA Issued By Leerink Partnrs

Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Akebia Therapeutics in a report issued on Monday, April 28th. Leerink Partnrs analyst R. Ruiz anticipates that the biopharmaceutical company will post earnings of ($0.01) per share for the quarter. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Akebia Therapeutics' current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for Akebia Therapeutics' Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.07) EPS, FY2026 earnings at $0.10 EPS, FY2027 earnings at $0.30 EPS and FY2028 earnings at $0.55 EPS.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last issued its quarterly earnings results on Thursday, March 13th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.05). The company had revenue of $46.50 million during the quarter, compared to analysts' expectations of $37.36 million.

A number of other brokerages have also recently commented on AKBA. Piper Sandler increased their price target on shares of Akebia Therapeutics from $4.00 to $6.00 and gave the company an "overweight" rating in a research note on Friday, March 14th. Jefferies Financial Group started coverage on Akebia Therapeutics in a report on Tuesday, April 1st. They set a "buy" rating and a $6.00 price target for the company. StockNews.com upgraded Akebia Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. HC Wainwright reiterated a "buy" rating and set a $7.50 target price on shares of Akebia Therapeutics in a research note on Friday, April 4th. Finally, Leerink Partners initiated coverage on Akebia Therapeutics in a research note on Monday, April 28th. They issued an "outperform" rating and a $7.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Akebia Therapeutics presently has a consensus rating of "Buy" and an average price target of $6.63.

Akebia Therapeutics Stock Up 2.5 %

Shares of NASDAQ:AKBA traded up $0.06 during midday trading on Thursday, hitting $2.45. The stock had a trading volume of 2,747,739 shares, compared to its average volume of 2,790,152. The company has a market cap of $641.37 million, a P/E ratio of -10.65 and a beta of 0.87. Akebia Therapeutics has a 12 month low of $0.80 and a 12 month high of $2.89. The business's 50-day simple moving average is $2.00 and its 200-day simple moving average is $1.96.

Institutional Investors Weigh In On Akebia Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. SRS Capital Advisors Inc. acquired a new position in Akebia Therapeutics in the 4th quarter valued at $26,000. PDS Planning Inc bought a new position in shares of Akebia Therapeutics in the fourth quarter worth $28,000. Mariner LLC acquired a new position in Akebia Therapeutics in the fourth quarter valued at about $28,000. Unified Investment Management lifted its position in Akebia Therapeutics by 47.8% during the first quarter. Unified Investment Management now owns 17,000 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 5,500 shares during the period. Finally, Cibc World Markets Corp acquired a new stake in Akebia Therapeutics during the fourth quarter worth about $37,000. 33.92% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Akebia Therapeutics news, SVP Steven Keith Burke sold 50,506 shares of Akebia Therapeutics stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $2.10, for a total value of $106,062.60. Following the completion of the sale, the senior vice president now owns 816,234 shares in the company, valued at $1,714,091.40. The trade was a 5.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Richard C. Malabre sold 30,202 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $2.10, for a total transaction of $63,424.20. Following the completion of the sale, the chief accounting officer now directly owns 280,248 shares of the company's stock, valued at $588,520.80. This represents a 9.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 280,579 shares of company stock worth $589,216 over the last three months. Insiders own 4.10% of the company's stock.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.